Skip to content Skip to footer
Thoughtspot_Saurabh_Chaubey

Role of Digital Twin Technology in Healthcare

Shots:  Developments in healthcare technologies are setting new standards at present and encouraging exploration into emerging technologies to advance care and enhance the lives of patients globally  Digital Twins are virtual replicas of objects, individuals, or systems spanning their life cycles  The article introduces the role of digital twins in the healthcare system, the advantages,…

Read more

Viewpoints_Uwe Gudat

Biocon Biologics at AAO 2024: Uwe Gudat in an Invigorating Discussion with PharmaShots

Shots: At the American Academy of Ophthalmology (AAO 2024), Biocon Biologics announced promising results from the extension study of its proposed biosimilar to aflibercept, MYL-1701P The study demonstrated comparable safety, efficacy, and immunogenicity between patients continuing MYL-1701P and those who switched from aflibercept to MYL-1701P Biocon Biologics' Chief Medical Officer, Uwe Gudat, discusses the groundbreaking…

Read more

Exclusive_Kenneth-Sake_2025

Exclusive: Kenneth Sake from Blueprint Medicines in an Enlightening Conversation with PharmaShots

Highlights:  Systemic mastocytosis (SM) is a rare disease caused by the abnormal accumulation of mast cells – a key part of the body’s immune system People with SM face potentially debilitating symptoms, such as skin lesions, diarrhoea, bone pain, fatigue and anaphylaxis, which can present challenges across various aspects of patients’ lives For more than…

Read more

Viewpoints_Caterina Brindicci

Enhancing Autoimmune Care: Caterina Brindicci from AstraZeneca in a Riveting Conversation with PharmaShots

Shots:   SLE-related diseases like CLE and IIM are characterized by strong type I interferon involvement. The proven efficacy of Saphnelo (anifrolumab) in SLE lays the foundation for its potential use in CLE and IIM  Recently, AstraZeneca initiated two new P-III trials, LAVENDER and JASMINE, to evaluate Saphnelo in cutaneous lupus erythematosus and idiopathic inflammatory myopathies …

Read more

Viewpoints_Mina Makar

A Retrospective Analysis on Cardiac Amyloidosis: Mina Makar from AstraZeneca in an Illuminating Conversation with PharmaShots

Shots:  A UK observational study spanning 17 years shows a 2.9-fold increase in Cardiac Amyloidosis diagnoses, highlighting significant progress in awareness among healthcare professionals and advancements in diagnostic tools  The study underscores the importance of improving the identification and treatment of Cardiac Amyloidosis, particularly in cases with overlapping conditions such as heart failure  Mina Makar,…

Read more

Viewpoints_Stephanie Fradette

Biogen at WMS 2024: Stephanie Fradette from Biogen in an Illuminating Dialogue Exchange with PharmaShots

Shots:  Biogen recently shared findings from the P-II/III DEVOTE study, which investigated the safety and efficacy of a higher dose regimen of Spinraza for the treatment of spinal muscular atrophy (SMA)  Stephanie Fradette, Head of Neuromuscular Development Unit at Biogen, joins PharmaShots for a stimulating conversation on Biogen's groundbreaking presentation at World Muscle Society 2024. …

Read more

Viewpoints_Mina Makar

Curbing Misfolded TTR with RNA Therapy: Mina Makar from AstraZeneca in a Stimulating Conversation with PharmaShots

Shots:  Misfolded TTR can lead to chronic conditions like ATTRv-PN or ATTR-CM. AstraZeneca’s Wainua (eplontersen) is a once-a-month RNA-targeted medication that suppresses TTR production  Mina Makar SVP and Commerical Lead of the Global Cardiovascular, Renal, and Metabolism (CVRM), Biopharmaceuticals Business Unit at AstraZeneca, sheds light on eplontersen and its ongoing P-III clinical trial on ATTR-CM …

Read more

Reuters Events Digital Health 2025

Reuters Events: Digital Health 2025

Join us for Reuters Events Digital Health 2025 on 12-13 May in Nashville, where we tackle the critical issues plaguing the healthcare sector today. As organizations face a stretched workforce and an outdated digital infrastructure, the urgency for transformation has never been greater. Current models of care are unsustainable, especially when addressing the diverse needs of an…

Read more

Reuters Events Pharma USA 2025

Reuters Events: Pharma USA 2025

Where disruption meets direction  In the past year, pharma has witnessed disruption in the external environment and internal restructure. We’ve reorganized for patients and customers – but it’s one thing to change a job title, another to transform outcomes. But how do you plan for the next wave of change across technology, regulations and expectations? For over…

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]